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INTRODUCTION

From the time of the first, attemots at cancer chemotherapy with
nitrogen mustards introduced at Yale by Gilman in 1948 (13), many classes
of compounds have been developed.

Among these are the alkylating agents

and antimetabolites as recently reviewed by Boy1 and (5), the corticosteroids
and antibiotics as reviewed by Arkin (2), and the folic arid antagonists,
reviewed by Jaenicke (25).

Despite the multiplicity of agents, only one

drug, methotrexate, has resulted in five year regressions in only one tumor,
choriocarcinoma in women (5).

All of these authors have further referred

to the toxicity, potentially fatal,

of most of the drugs at the doses that

must be used for tumor regression.

Recently interest has turned toward toe

use of the halogenated pyrimidines,

summarized by Welch, Calabresi and

Prusoff 1963 (39).
Within the last decade, the technical, side of radiotherapy has rapid¬
ly progressed with the addition of greatly improved supravoltage x-ray
machines generating 1 to 70 million electron volts and tel.etherapy
easily maintained cobalt 60 sources, plus the addition of isotope therapy
(29).

However, radiotherapy still is not a totally satisfying means of

tumor therapy.

Our attention has been drawn to the possibility of augment¬

ing the effectiveness of radiation on the cell or sensitizing the cel1 to
radiation by combination of x-ray with various chemical

agents in the cone

of increasing the therapeutic effect while holding toxic effects within
acceptible levels.

Furthermore,

it has been our purpose to attempt to dis¬

cover if an optimum time-sequence of administration exists in such comb na¬
tion regimens.

.

•*

...

>

Bane et al (4) has reviewed the field of combination therapy divi¬
ding the various chemical agents used,

into carcinostatic agents, agents

that increase susceptibility to x-ray without an effect of their own
sitizers), and secondary radiators or carriers.

(sen¬

Among the carcinostatic

agents discussed are the alkylating agents, urethane and the purine ana 1c'rites
while Oo, various dyes, and synkavit are mentioned among the sensitizers'.
Spengler et al (35) used L-triiodothyronine in combination with 450f‘r x-ray
on mouse breast tumors but noted no significant difference between combined
therapy and x-ray alone.

After an initial tissue edema, tumors did regress

in size, but there was also an increase in the mortality from irradiation
used in combination with the drug.

Work has also been done using Vasodilator

(acetylcholine and tolazoline) with 2600r x-ray, but only suggestive rises in
the expected oxygen effect have been shown
Goldin and Mantel

(27),

Attempts have been made by

(15) to obtain therapeutic synergism (an effect greater

than would he expected by adding the results of each therapy alone) by using
two drugs together without x-ray.

In most cases, toxicity as well as ecf*"-c«~ . ve

ness was reduced, but some ’enhanced effectiveness5 was obtained with cii.rovorura factor given in advance of aminopterin,

Leucutia (30^ obtained mai .■

and long palliative effects with colloidal lead orthophosphate and x-ray

m

bone neoplasms and with neostibosan and X-ray in multiple myeloma.
Kligerman (26) has evaluated some of the various chemicals that have
been used in combination with x-ray and the evidence that exists for radio¬
sensitization.

Included are the original studies of the Yale group on

5-Iododeoxyuridine■
pyrimidine analogues.

Presently great interest is centered in the halogenafced
Szybalski (36) has demonstrated, with diugs sue.1

’a

S~chl.orqdeoxyu.ridine, 5-browodeoxyuridine, and 5-Iododeoxyuridine, that
there is ^Corporation of these synthetic chemicals into strands of
Enough time must be allowed so that the BNA molecules can incorporate the
drugs.

Originally it was believed that substitution was needed in at least

two strands to obtain a therapeutic effect.

However,

sensitisation to j

lesser degree does occur with single strand substitution.

Thus some feel

that, it might be best to give the drug over several days to a growing tumos
batski believes the WA seems to be sensitized because of an intensive
increase in radiation lability and a partial or complete loss of the Dv-.\
molecules’ ability to undergo enzymatic or non-enrymat.ic repair.

Bag'sbav f"v

used 5-FU in vitro (with Hela cells) and demonstrated that 5--H1 a’one nr■u
enhanced the growth of the Hela cells at low concentration, but,

•

if given fmw

hours prior to 10-600r x-ray, a greater decrease in the number of cells we
observed, than with x-ray alone,

A 1.4 greater effect of rad nation by the

addition of 5-FU was observed (3),

Clinically, great interest has turned to 5-Fluorouracil,

a pyrimidine

analogue synthesized by Reidelberger and co-workers (21-24), because of its
singular success as being one of the few drugs with any effect on

■ n.

especially carcinomas of the breast, ovary, large bowel, rectum and hepat >mr
Significant regression, unfortunately,
the toxic level

is seen only when the diug 1s use 1

Extensive clinical and laboratory trials- are now in prog-ess

on the use of 5-FU attempting to lower its toxicity or maintain it within
acceptable levels by combination therapy with x-ray,
The antimetabolite itself

5-Fluorouracil

(5-FU) has been found to

exert its antineoplastic effect by inhibiting the formation of thymidylic

3-

-

:

1

d -iecess ir

tr

the formation of de soxyriboneiiclei<

■ id (1) A

:

acting as an antagonist, to ribonucleic acid (P.V.k) synthesis .
orotic acid,
cytosine,

the precursor compound, is converted to the pyrimidines,

thymine, and uracil..

Heidelberger (211 has shown that 5“FT1 cart

take the place of uracil in metabolism without losing its- fluoride Ion
which passes for hydrogen and blocks the position of normal methyl at ion cf
the uracil,

Thus 5-FU can go through normal anabolism to give a fraudulent

DMA as well as in some way inhibiting its formation.
Thymidinedesoxyribol
phosphate (TDRP) is known to be formed from Uridinedesoxyribophosphete (UUFF)
by a methylation reaction catalyzed by thymidylate synthetase in the presence
of tetrahydrofolic acid,

5-FU is metabolized to form 5 fluoro 2 deoxyuridine

5 monophosphate which in turn has been discovered to be the substance that
inhibits thymidylate synthetase activity.

This inhibition seems to be the

crux of the chemotherapeutic action of 5-FU,

Combination therapy with 5-t-i

does not seem to cause any additive inhibition of thymidylate synthetase.
- Instead, Heidelberger has evidence that the presence of irradiation causes
a block in the induced formation of thymidine kinase before this enzyme has
a chance to rise as it would in normal conditions.

This may play some rote

in sensitization but exactly bow combination therapy exerts its effect i s
known.

Heidelberger and his co-workers have thoroughly investigated t. e

action of 5-FU illustrating the decreased inhibition of thymidylate synthetase
in resistant tumors,
failure of formate

the requirement of ATP for the action of 5-Fb . and the
to he incorporated in TINA thymine in the presenc e o-

5 fluoro 2 deoxyuridine 5 monophosphate
Experiments with 5-FU alone have demonstrated variable effects on a
wide variety of neoplasms.

Heidelberger (221 has obtained the foil c'. i -•->
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tiff

775 mammary adenocarcinoma

Slightly arresting

Sarcoma 180

Careinostatic

Sarcoma A-l

Slightly arresting

o

E0771 Mammary adenocarcinoma

Inhibiting

F1exner-JobXina carcinome

Initially effective

Walker 256 Carcinoma

Slightly effective

Ehrlich Ascites Carcinoma

Causes regression

L1210 Leukemia

Increased survival time

Yoshida Ascites sarcoma

Increased survival time

Movikoff hepatoma

Increased survival time

Vermund et al (37) investigated the use of combination therapy on
transplanted adenocarcinomas in mice using 300r daily for 5 days amounting
to a total of 5. lOOr of x-ray in 23 days and 35 mg/lcg of 5-FU for 5 days
then 17 5 mg/kg twice weekly for two weeks.

This regimen of therapy gave

an average survival time in Swiss albino mice with sarcoma of 73.9 and 62 °
days as against an average survival of 25.6 and 18,8 days in the centre1
mice.

Eight out of 19 mice showed complete regression of tumor with 5-FU

and x-ray whereas x-ray alone merely inhibited tumor growth and caused no
regression.

Z mice with an adenocarcinoma seemed to respond to combination

5-FU and x-ray therapy having an average survival of 72.8 and 71.2 days as
compared with 42 and 53.8 days in the control groups.
disappeared completely.
of the effect on humans.

Only one of the tumor

These results are difficult to evaluate in terms
The resxilts in far advanced malignancy have,

the greater part, been inconclusive. Generally speaking,

5-

-

for

5-FU given alone

mice

fails

breast,

to cause regression yet

colon and ovary

(37).

tained with spontaneous and
are unknown.

Also,

it: will,

in human carcinomas • i

The validity of comparing the

transplanted tumors

the

results ob¬

in mice to human tumors

the response of mouse tumors to combination therapy

has been noted by Heidelberger

(22)

to vary but,

in general,

he has noticed

o

an appreciable tumor inhibiting effect especially with 5-FU and x-ray

in

combination on sarcoma 180 and

is

of potentiation

pv< !e

(22).

In humans,
Greene

775 mammary adenocarcinoma where there

Gold and Hall

(14),Winston et al

(40),

and Olson and

(31), have found that 5-FU alone has caused regression in 19.6% of all

carcinomas treated with the longest remissions noted in cancers of the breast
and uterus

(50.8% experiencing some relief).

Hall et als

that 5-FU is most effective in cancers of the breast,
rectum and

(17) have found

ovary,

large intestine,

in hepatomas.

The conventional doses of 5-FU in therapy are 15 mg/kg/day for 5 days
by

rapid IV injection (not to exceed 1 gm per day) and

day until toxicity appears.

Although possessing a definite anti-tumor effect,

5-FU has a very narrow therapeutic
toxicity among their patients).

index (Olson et al

leukopenia

(31).

Delayed effects

skin

(16).

ment

(Olson et al)

(70%),

(31) noting

(31);

nausea,

vomiting,

or diarrhea

anemia and ulceration of the gastro-intestinal

include alopecia and

and Winston et al

euphoria when using 5-FU.

tract

increased pigmentation of the

A sudden agranulocytosis can occur after cessation of
(31)

184 rata!

The most common toxicities consist of stoma:.

(40% Freuge'rson & Humphrey in Olson et al
(87%)■

7.5 mg/kg every other

(40)

noted a high

the

treat¬

frequency of

Recent work has been aimed at methods of allevi-t i

this high toxicity while maintaining the anti-tumor effect

6-
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in toxieit}
although

the

recently,
In

has been obtained by simply -prolongi xg

Imi

is

incidence of sclerosing phlebitis then increases

ratio
(12).

the concoromitant use of 5-FU and x-ray therapy has been.

Inoperable tumors of humans, Hall et als

pushed to

toxic doses,
,

time
More

invesLigac-

(17) have found that

and 2000 - 2250r x-ray over a period of several wee!

o

does produce additive or potentiating effects
ovary,

th«

large bowel,

rectum and hepatomas..

ulceration of the G.I.

tract

diarrhea,

the breast,

Tumors of the lungs,

pancreas and kidney did not seem to respond
toxicities such•as stomatitis,

in carcinomas of

(17),

Yet,

despite

stomach,
all

suppression of hematopoesis,

still occurred.

Frank et al

and

(12) has been able

to alleviate some of the toxicity of 5-FU by prolonging its administration
time

to 8 hours of I.V.

infusion.

Using this prolonged administration of

conventional doses of 5-FU in combination with 1900~7000r x-ray,
regression of tumor size
operable carcinomas

th"

they obta“nr

in 50% of their patients with assorted types of in¬

(12).

Hall and Good

(16)

of advanced neoplastic disease with 5-FU and

also investigating treatment
irradiation,

found

that the be

therapeutic effects were obtained when the toxicities of 5-FU first appeared
They noticed

that with combination therapy,

gastrointestinal ulcers and

suppression of hematopoesis occurred along with the desired antineoplasti
results in carcinomas of
In 1960,

the head and neck,

Foye et als

(11)

ovary, and breast.

tried using 5-FU in non-toxic, doses

(15- mg/kg for 5 days followed by 2.5 mg/kg tv; ice weekly) with
x-ray and obtained
lung and

2000r tote’

significant regression of epidermoid carcinomas of t' e

larynx, which normally do not respond to the drug alone.

using the conventional toxic doses of 5-FU (15 mg 'kg for
every other day

til 1

toxicity) with

5 days,

Crews

(8‘;

7,5 m" 'kg

? Mev radiation on 33 patients with

t

advanced solid tumors.i noted 'vomiting, diarrhea?,
in a majority. of the patients followed

stomatitis

and leuk pent,

Vascular co! lapse and -dopcr’a

vas noticed in 507 while dermatitis and phlebitis were a1--., < .irnmon occurrence
(R),

Eleven patients received good palliation with a decrease i.n tumor

relief of pain, and weight gain of a 4-6 month duration (8).

Ten patients

o

had poor palliation with only temporary regression of 2-3 months followed
by. a regrowth or•relapse (8).
soever (8).

Finally,

9 patients showed no response what¬

Crews, with the exception of the results on G.I.

tumors, noted

no indication for a potentiating effect with combination therapy, on solid
tumors (8)..

Somewhat unusual

results were found by Allaire efc al

(1) when

they reported that objective improvement was noted with combined therapy
(conventional doses of 5-FU and 2000r x-ray over 2-4 weeks) on tumors of the
pancreas, stomach and bronchus.

They obtained only promising results on

neoplasms of the gastrointestinal tract and lungs.

Cornell et al

(7) found

that combination of 5-FIT and x-ray only caused arrested growth of tumors wit1
I

a stable course followed by further growth instead of regression.

On the

other hand, Faye et -al.s (101 claim that concomitant use of 5-FIT (conventional
dose) and local irradiation (2000r) gave a greater degree and higher incidence
of tumor regression than is obtainable with either mode of therapy alone.
The effects noted also exceed those that would be expected on the basis or
additivitv alone (10).

Foye (10) thus concludes that he has observed a

synergistive effect with combined therapy.
Kligerman,

Recently, however, von Fssen,

and Calabresi (35) in. a controlled study in humans,

failed to

demonstrate a significant alteration in the response of multiple metastatic
tumors to x-ray by the addition of 5-FU.

8-
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Tt i« obvious that a wide difference of opinion exists
effectiveness of 5-FU and x-ray used in combination.

to the

In addition,

the

question has recently been raised in any combination drug and radiotherapy
as to whether an optimum time-sequence for administration of the treatment
modes exist (28),

The present study was undertaken to find an optimum

time-sequence of administration of 5-FU and x-ray and in the process to
evaluate the effectiveness of combination therapy. '

■I!
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MATERIAL AND METHOD?

A mammary adenocarcinoma which arose spontaneously in

our

C3I? colony

and had been subcultured for many generations was transplanted into the
D

left thigh of 215 mice.
C3H/JAX.

60% of these mice were C3H/CGRI, and the remainder

All but 42 were males.

In general, the mice were 4-6 months old

at. the start of the experiment.
A mouse carrying the tumor was sacrificed without anesthesia, the
tumor being removed and minced under saline.

Fifty C3H mice were then

innoculated with minced tumor by a size 13 trocar in the left'thigh.

About

10-1? days after transplantation, 42 of the 50 mice whose tumors were suit.(blmeasurable were selected.

Only tumors of fairly uniform size (4-0 mm average

diameter) were used in order to reduce bias.
randomly to 7 groups of about

These 42 mice were then assigned

animals each.

6

X-ray treatment, was carried out in X/4n thick boxes with the animal1:
left leg held out by a string and placed directly under the 1.5 cm. cone.

No

anesthesia was used.
With day #0 as the day of initiation of treatnu
measured on the following fixed days: #1, 2, 3, 4, 5,
19, 26, 33, 40.

, 7, 9,

6

11,

13, 15,

Tumor volume was calculated by multiplying the three dimen¬

sions together, as measured by a standard caliper, and multiplying this
figure by .524.

Most of the treated mice and all of the untreated ones

died of metatasis within this 40 day observation period.

For the duration

of the period of observation,the various groups were assigned randomly to
several

cages to avoid the cage effect as described by Raventos (32).

10-

-

In

this way, distortion of the final results by events within the population
of any one cage was reduced.
Therapy, as mentioned, consisted of both x-irradiation and 5-Fluorouracii.

One intraperitoneal injection of 125 mg/kg of 5-Fluorouracil

(an

as determined by preliminary dose-response studies but an LD.q in this expe
iment) was used throughout.
acceptable mortality rate.

This was an effective dose with the highest
The x-ray dose chosen (based on prior experimer

was one local treatment of SOOOr, an EDg for long-term regression of local
These doses were selected to insure that any additive or enhanced efforts
would not be masked.
Filter.

The machine was set at 250Rv,

15 mg, with a 2 mm AL

.The cone length was 3 cm and the distance from the cone to the tar

get was negligible.

Victoreen readings of the lOOOr chamber timed for one

minute of machine output averaged about 900r/min, corrected.
The treatment groups received the following reg?Lmens:
Group I « received local x-ray dose of 5000r.
Group IT. - received, an intra-peritoneal injection of 5-FU,
dose - 125 mg/kg (LDiq).
Group III - received the injection of 5-FU and If minutes
later received SOOOr x-ray.
Group IV - received the injection of 5-FU and 3 hours later
received 5000r x-ray.
Group V - received the injection of 5-FU and 24 hours later
received SOOOr x-ray.
Croup VI - received SOOOr x-ray and 24 hours later received
the injection of 5-FU.
Group VII - served as the control and received no treatment.

■

-

•

-

Each lot of about 42 mice was treated as outlined above and con¬
sidered ss a separate experiment m

run.

The total study was composed

of 5 such identical experiments each containing the same 7 treatment
groups (total of 215 mice) outlined above so as to help avoid chance
events and spurious results distorting the final, results.

In order to

minimize, the influence of host factors, only the rate of decree/..-- in the
size of tumors was used in comparing the several treatment schedules in
a model system,

little emphasis being placed or. cure or survival rates.

The latter are recorded, however.

RESULTS

Emphasis is placed on the progression of tumor volume:-, following the
various modesiof therapy.

Other parameters followed included *curc1 , death.

and survival rates.
The variability of response of the individual mice was so great

differences within each group were greater than, the differences between th •
groups.

The mice which died early were considered dead ol toxicity.
.

groups for each run and the corresponding groups from each run were
together for comparison.

In figure 1, the tumor sizes of the groups rc-ceiv

x-ray alone (Group I) are plotted, the number of surviving mice being indi¬
cated by a number above each point on the graph.

It should be noted at th:

point that Run 5 was the only run employing female C?H mice.
was not a factor affecting the results.
(figure

2),

The groups with 5-FIT alone (Croup II)

with the exception of one mouse, show ho response in an].

the drug alone.
(see figure

Sex. however4

3)

Giving the drug 15 minutes prior to x-ray therapy (Group HI'

seems to have caused an inhibition of tumor growths after 3- '•

days lasting until about the fifteenth day.
tumor invariably resumed.

At this point, growth of the

The results of the groups receiving 5-FU three

hours ptior to x-ray (Group IV)

(Sec figure 4) are similar to Group HI.

There is inhibition in tumor growth and even some regression of tumor size
followed by regrowth of the tumor in greater than 75% of the remaining mice.
The groups receiving 5-FU 24 hours prior to x-ray (Group V)

(See figure 5

resemble Group IV.with the exception of the existence of a few create ' ?.xtrem

13-
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in tumor si.se.

In the grouns receiving x-ray V\ hours prior to 5-FIT (Group VI)

(See figure 6) , there are again quite variable but not significantly dif fe’-en:
results from those of the other combined treatment groups.
controls (Group VII)

The tumors of the

(figure 7) grow quite rapidly as is expected.

One mouse

in Run 3 had an unusually long survival, dying only after a very large tumor
had grown.
For further consolidation of the results, all of the tumor volumes in
each treatment group, were averaged together and plotted as one curve (figure s).
'he general trend.for each group is clearly illustrated, but one must be mindful
that the fewer the surviving mice, the less representative are the average tumor
sizes.

Standard errors of the mean were calculated at each day of observation

and are represented on. separate graphs for each treatment group (figures 9-15).
The standard errors, based only on the surviving animals, became unreliable after
day ip because of attenuation of the colony dxxe to tumor deaths.

The standard

error.for each group at day 19 is recorded on the composite graph (figure 8).
The number of survivors in each treatment group at fixed days after treatment
is shown in Table I.
Up to the 19th day, there is no statistically significant difference
between the group receiving x-ray alone (Group I) and any of the combination
therapy groups (Groups III-VI).

After the 1.9th day-, a general increase, .in

average tumor volume, is noted in all of the combination therapy groups, where¬
as a slight decrease is seen in the group with x-ray alone (Group I),
"•ate

This

difference cannot be subjected to statistical analysis due to the sma11

number of survivors.

Likewise, there is little difference between the

con¬

trol group (Group VII) and the group receiving chemotherapy alone (Group Tf'.
The last point on the latter curve represents only one mouse whose t ;mo' had

TABLE 1

StflWlVwS

Day

0

T“T

9

IS

1
U
1

--L

40

“ !

Group I
X-ray- 5000r

SO

30

»:

29

SO

24

24

■
Group U
SI

SI

ss

.4

!

3i

32

24

24

24

32

32

27

26

2$

31

32

2$

30

28

23

29

20

22

S

1

IS

9

29

2$

s

(4

5-ru

24

23

| 2$

8

22

29

10

W

3

2

Group m
5-FU 15 MIA.
Prior to 5000 r

22

|

Group IV

5-ru

3 Era.

Prior to $000 r

S-Ftf 24 Era.
Prior to 5000 r

__:

Group V

Group VI
HO 24 Era.
Mtor $000 r

Group VJX

Control

'

9

continuously increased in size after chemotherapy, alone until
and then began to regress until the death of the mouse.
point should be disregarded.

Therefore, this

This is the. only incidence of

in either of these 2 groups (IX or VII).

the 19th day

tumor

regression

Both of these groups, however,

differ significantly from all those receiving x-ray.

It is noteworthy that

in no group was the final average tumor volume smaller than the starting
average tumor volumes, although the group with x-ray alone (Group I) approached
this.

(Figures 9-15 show the average tumor sizes of each group separately

with the standard errors included).

Since we were working with transplanted tumors, the most meaningful
data is represented by the regression and growth rates.
fluence tumor ’cures").

However, Tables 2M and 2b are included to show de¬

tailed data on permanent regression of the primary tumor
followed by recurrence.
Tables 3a and 3b,

(Host factors in¬

md complete regression

The causes of death following treatment are listed in

Most mice died of metastases from the implanted tumor in¬

cluding those that obtained temporary "cures’ at the original tumor-site
(tumor no longer palpable or observable).

The mice listed as "permanent

regression" had no evidence of original tumor or metastasis when sacrificed
4-5 months after the 40 day observation period.

The x-ray dose (5000r)

given to Group I gave a temporary local cure of.40% (ED^q for regression
of local tumor followed by recurrence).

This same degree of effectiveness was not

noted in any of the other groups receiving 5-FU in addition to the same x-ray
dose.
ranged

In fact, the percentage of temporary complete regression of local tumor
from a low of only 25% in one of the combination groups to a high of

36% in one of the other combination groups, the difference between groups not
being significant.

An EFg

for permanent regression of local tumor was obtained

l

PVf
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5
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|
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1/6

1/6

0/7

1/7
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2/7

3/6

1/6

0/7

3/6

1/6

0/6
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IV
5-FU 3 Hrs.
Prior to 5000r

V
5-FU 24 Hrs.
Prior to 5000r

VI
5-FU 24 Hrs.
After 5000r

Control

0/6

0/7

0/6

with 5000r„
the mice.

That is to say, permanent cures occurred in 13 or 8% of all
No cures occurred in the mice treated with drug alone..

The rest

of the mice, i.e. those that were not cured or did not die. of metastases,
(the large-majority of which were in the combined therapy groups) died earl-'
in the course of the experiment from a side reaction of therapy.

The doses

of 5-FU given by itself was a LD.Q under experimental conditions as indicated
by the toxicity found in Group II (5-FU alone).

The other groups receiving

5-FU (the combined therapy groups) had a slightly higher incidence of toxicity.
In fact, there was an average of 23-30% fatal, toxic it ies with combined therapy
as against no such cases with x-ray alone.

The miscellaneous causes of death

were few and included events such as injection damage and infections that were
present in the colony at the time..

16-
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DISCUSSION

The above results revealed that not only did the timing of administration of therapy fail to play an important role, but also no combina¬
tion regimen seemed to give greater antineoplastic effect than was noted
with x-ray therapy alone.

The lack of potentiation of radiation by 5-FU

in these experiments correlate with the .clinical report of von Essen
co-workers (38).

This study, using x-ray alone, 5-FU alone, and combination

therapy on multiple metastatic tumors within individual patients, failed
to demonstrate a significant alteration of response of tumor to irradia¬
tion by the addition of 5-FU.
There was a wide range in degree of effectiveness among the mice
responding to therapy.

Some mice did not respond at all to a therapy

schedule that in other mice would cause a disappearance of the original
tumor.

Treatment in some was sufficient only to cause transitory inhibition

in tumor growth followed by resumption of the previous growth rate whereas
in others, regression in size or even complete disappearance was fol
by regrowth.

In each case, it appeared as though the administered

therapy

regimen was only partially carcinolytic, the remaining viable cells account¬
ing for the following regrowth.

In some cases, these remaining cancer cell.,

did not apparently have aa opportunity to regrow since fatal metastase^ had
already taken place.
There is the possibility that the administration of 5-FU even ?J\
hours prior to x-ray was inadequate time for full sensitization.

Yet Bagsha

(3) has reported obtaining enhanced x-ray effects on Hela cells when 5-FU
was added only 4 hours prior to x-ray.

Szybalski (36), on the other hand,

has noted that the sensitizing effects of purine and pyrimidine analogues in
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general appear to be greatest approximately 4 days after drug exposure-.
He, however, has worked mainly with EUDR and IUDR which is incorporated
into the DNA.

In our instance, nonetheless, there was not; even the

slightest indication of a minimal sensitising effect by the drug in a
hour period.

2k

A possibility exists that, either the drug or the x-ray given-

first might impede rather than enhance the other’s effect.

Both the effect

of 5-FU and irradiation depend to a large degree on a viable, and rapidly
growing tumor.

Administration of either drug or x-ray first could damage

the tumor sufficiently so as to diminish the effect of the other treatment
following thereafter.

Other investigators have noted enhanced effects :>n

mouse tumors with combination therapy.

Vermund (37) reported enhanced sur¬

vivals with mouse sarcomas and adenocarcinomas.

His results, however, ar...

neither consistent, nor do they meet the criteria for true sensitization
set forth by Schoeniger et al (34).
Since no difference in any of the groups with combination therapy was
found, the lack of an optimum time-sequence of administration is not eurprlMn
The average tumor volumes of all the mice receiving any of the
regimens remained within one standard error of each other.

combined

th'n

This cannot b

to mean that there, is no such optimum, but there was no such indication here.
Since transplanted tumors have been used, not much reliability is being
placed on the cures, permanent or temporary, obtained.

The effect of var' m

host factors on transplanted tumors have been known to play an important ro’e
in determining

the

effectiveness of cure of a certain mode of

Fur¬

therapy.

thermore, tumors that have been transplanted in one strain for many gene-it r ■
seem to become much more amenable to cure.

but these factors are not involved to the same degree in rate of dec re.'.e
tumor size.

■

The reasons for this are not

This 1 utter response is thus a more reli ble indication

f t1

1

efficacy of the therapy here,

tt is interesting, however,

that all groups

in this study, with the exception of the controls and those receiving drug
alone, had some scattered permanent cures (long-term regression of local
tumor)..

All of the mice with temporary regression of local tumor eventual1;'

died of metastases as did the vast majority of all mice regardless of treat¬
ment group.

Only about four revealed no metastases at autopsy and death

was assumed to be due to the large-sized, original tumor.

The metastases

were in. general, throughout the lymphatic system, especially in the mesenteric
nodes

and adrenal glands.

Other causes of death are listed in Table 3.

The observation that the drug itself had little effect on tumor
growth is consistent with that of Vermund who also has noted that 5-FU al :>ne
fails to cause regression in mouse- adenocarcinomas the way it will on human
cancers of the breast, colon and ovary (37),
used, an ID,^

The dose of the drug which we

as determined in a pilot study, was sufficient to cause a

197 fatal toxicity under experimental conditions and thus was present in sub¬
stantial amounts

within the mice treated.

This was a dose considered to be

reasonably effective and one that with the x-ray dose used -/5000
for temporary complete regression of local tumor and EP

s

^r'/4f)

for permanent

regression of local tumor) would not obscure any additive effect that might
be found.

No deaths from treatment toxicity were noted in the controls or

the groups receiving x-ray alone (the only groups not receiving 5-FU).
the fatalities due to treatment were considered drug toxicities, at the most
being enhanced by irradiation as evidenced by the 23-to 3011 fatal

toxic it]

in the combined therapy groups as opposed to 197 with drug alone.

This i-
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not at all an unfamiliar finding.
index of 5-FIT as being a hazard.

Frank (12) baa cited the

lov

therapeu?" ‘

When used with x-ray therapy he noted a

higher rate of toxicity, but unlike the results here, he also claimed evidence
for svnergism of therapeutic effects.

(Drug toxiciti.es listed in Table

.

This experiment has been chosen as a model for other possible timesequence studies of combination drug and radiotherapy on tumors.

Other t-?re ¬

sequences including use of fractionated x-ray doses and other drugs such a5-FUDR and S-ItTUR should be investigated.

In addition,

it would be profi tabi •-

to attempt studies to synchronize tumor cells to 5-FU, i..e. halt ceils at
sensitive part of their cycle with 5-FU, then using fractionated doses of
x-ray so as to obtain greater therapeutic effect.
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SUMMARY

The effect of combination 5-FU and radiotherapy was tested by
measuring the size of a transplanted adenocarcinoma in CgH mice on certain
fixed days after various sequences of drug and irradiation.
effective doses of 5-FU (125 mg/kg by single I.P.
x-ray (5000r locally, an EDg
were used.
alone;

injection, an LD,Q) and

for permanent regression of local tumors)

The seven treatment groups were:

(III) drug 15- rains, prior to x-ray;

(V) drug 24 hours prior to x-ray;
no treatment.

Reasonably

(I) X-ray alone;

(II) drug

(IV) drug 3 hours-prior to x-r.-iy

(VI) x-ray 24 hours prior to drug;

(VII)

The total study was divided into five smaller and identi¬

cal experiments, with ral.ee being randomly assigned to cages after therapy,
so as to avoid chance events and spurious findings biasing the total result

.

No significant difference was noted between those, receiving x-ra;
alone and any other combination of x-ray and drug.

Furthermore , there v:rs on I

slight difference in growth rate between the controls and the mice receiving
drug alone.

Greater variation in response was noted within each group than

between the groups.
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